Pattern and prognostic factors in patients with malignant ascites: a retrospective study
- PMID: 17298959
- DOI: 10.1093/annonc/mdl499
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Abstract
Background: Malignant ascites is a manifestation of end stage events in a variety of cancers and associated with a poor prognosis. We evaluated the pattern of cancers causing malignant ascites and factors affecting survival.
Patients and methods: Patients coded with the International Classification of Diseases-9 coding system for malignant ascites over a 2-year period were reviewed. The clinicopathological data and patients' survival were compared among cancer groups.
Results: There were 209 patients (140 females and 69 males), median age being 67 (30-98) years. The commonest cancer was ovarian followed by gastrointestinal (GI) cancers. Fifty-eight per cent of the patients had symptoms related to the ascites. Liver metastases were significantly commoner in the GI cancers (P = 0.0001). Fifty-four per cent of our patients presented with ascites at the initial diagnosis of their cancer. Paracentesis was given to 112, diuretics to 70 and chemotherapy to 103 patients. The median survival following diagnosis of ascites was 5.7 months. Ovarian cancer favoured longer survival while low serum albumin, low serum protein and liver metastases adversely affected survival. The independent prognostic factors for survival were cancer type, liver metastases and serum albumin.
Conclusion: The identified independent prognostic factors should be used to select patients for multimodality therapy for adequate palliation.
Similar articles
-
Malignant ascites: demographics, therapeutic efficacy and predictors of survival.Can J Oncol. 1996 Nov;6(2):474-80. Can J Oncol. 1996. PMID: 12056099
-
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.Eur J Cancer. 2016 Aug;63:127-34. doi: 10.1016/j.ejca.2016.05.004. Epub 2016 Jun 15. Eur J Cancer. 2016. PMID: 27314448 Clinical Trial.
-
Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA.Gastrointest Endosc. 2010 Feb;71(2):260-5. doi: 10.1016/j.gie.2009.08.025. Epub 2009 Nov 17. Gastrointest Endosc. 2010. PMID: 19922924
-
[Pathogenesis and management of refractory malignant ascites].Bull Cancer. 2011 Jun;98(6):679-87. doi: 10.1684/bdc.2011.1373. Bull Cancer. 2011. PMID: 21636346 Review. French.
-
[Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].Bull Cancer. 2015 Nov;102(11):940-5. doi: 10.1016/j.bulcan.2015.09.002. Epub 2015 Oct 23. Bull Cancer. 2015. PMID: 26477275 Review. French.
Cited by
-
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.Int J Mol Sci. 2020 Sep 7;21(18):6533. doi: 10.3390/ijms21186533. Int J Mol Sci. 2020. PMID: 32906729 Free PMC article.
-
Advances in the treatment of malignant ascites in China.Support Care Cancer. 2024 Jan 11;32(2):97. doi: 10.1007/s00520-023-08299-w. Support Care Cancer. 2024. PMID: 38200158 Review.
-
Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway.Theranostics. 2020 Jul 11;10(20):9083-9099. doi: 10.7150/thno.46467. eCollection 2020. Theranostics. 2020. PMID: 32802180 Free PMC article.
-
Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.BMC Cancer. 2018 Dec 10;18(1):1232. doi: 10.1186/s12885-018-5152-5. BMC Cancer. 2018. PMID: 30526541 Free PMC article.
-
Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients.Am J Reprod Immunol. 2020 Sep;84(3):e13284. doi: 10.1111/aji.13284. Epub 2020 Jun 30. Am J Reprod Immunol. 2020. PMID: 32524661 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical